RSV Prevention

Cross-source consensus on RSV Prevention from 1 sources and 5 claims.

1 sources · 5 claims

Uses

RSV infection remained high among children aged 0-2 years and then declined from age 3. — Cross-sectional study of respiratory virus infections in upper respiratory tract infection patients: post-COVID-19 pandemic trends in Sichuan, China
Children aged 0-2 years were identified as a high-risk RSV population. — Cross-sectional study of respiratory virus infections in upper respiratory tract infection patients: post-COVID-19 pandemic trends in Sichuan, China
The study advised local health authorities to consider maternal immunisation or RSV vaccination for children aged 0-2 years. — Cross-sectional study of respiratory virus infections in upper respiratory tract infection patients: post-COVID-19 pandemic trends in Sichuan, China
The study recommended accelerating development and introduction of more affordable RSV vaccines in China. — Cross-sectional study of respiratory virus infections in upper respiratory tract infection patients: post-COVID-19 pandemic trends in Sichuan, China
RSV vaccine access in China is limited because nirsevimab is relatively expensive. — Cross-sectional study of respiratory virus infections in upper respiratory tract infection patients: post-COVID-19 pandemic trends in Sichuan, China